Chlamydia testing: where are we now? Recruiting high-risk women to a pilot STI screening trial (vol 89, pg 556, 2013)

被引：0

|

作者：

Hunjan, T.

Kerry, S. R.

Normansell, R.

Sadiq, S. Tariq

机构：

来源：

SEXUALLY TRANSMITTED INFECTIONS | 2014年 / 90卷 / 01期

关键词：

D O I：

10.1136/sextrans-2013-051151corr1

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

引用

收藏

页数：1

相关论文

共 24 条

[21] Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial (vol 383, pg 1041, 2014)
Cuzick, J.
Sestak, I
Forbes, J. F.
LANCET, 2014, 383 (9922): : 1040 - 1040
[22] Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II):an international, double-blind,randomised placebo-controlled trial (vol 383, pg 1041, 2014)
Cuzick, J.
Forbes, J.F.
LANCET, 2017, 389 (10073): : 1010 - 1010
[23] Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial (vol 20, pg 1273, 2019)
de Boer, S. M.
Powell, M. E.
Mileshkin, L.
LANCET ONCOLOGY, 2019, 20 (09): : E468 - E468
[24] Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial (vol 19, pg 295, 2018)
de Boer, S. M.
Powell, M. E.
Mileshkin, L.
LANCET ONCOLOGY, 2018, 19 (04): : E184 - E184